NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

Advances in cancer genetics, such as increased use of multigene panel testing, has transformed the clinical approach to testing at-risk patients and their families. Based on these rapid advances, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast and Ovarian (now Breast, Ovarian, and Pancreatic) have undergone some major revisions for the 2020 update. These revisions include reorganization of the guidelines by disease and syndrome type; inclusion of criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2; the addition of pancreatic cancer to the title, with new information added about pancreas screening and genes associated with pancreatic cancer; clarification of testing indications for the purpose of systemic therapy decision-making; and new recommendations for testing of people with Ashkenazi Jewish ancestry.


Read full Guideline